AB DigiHealth Inc. is an innovative biomedical startup dedicated to AI-driven reproductive healthcare solutions. Our core team is composed of experts in genomics, artificial intelligence, and clinical reproductive medicine. 

We offer high-quality next-generation sequencing (NGS) services, integrated with our proprietary bioinformatics analysis and AI-assisted decision-making system to maximize automation and precision. Our mission is to bridge the gap between scientific discoveries and clinical applications, providing the world with a comprehensive solution for maternal-fetal precision medicine.

Our flagship product, icONE, is designed for couples undergoing IVF treatment. By leveraging AI to integrate genomic data from embryos and maternal physiological parameters, icONE predicts the implantation potential of embryos with an accuracy rate of up to 92%. It assists clinicians in selecting the highest-quality embryo for transfer.

Prospective clinical trials have shown that icONE significantly improves pregnancy success rates to as high as 81%, helping more families achieve their dreams of successful conception. icONE has been officially registered as an FDA Class I Software as a Medical Device (SaMD) in the U.S., marking a major milestone in our global commercialization strategy.

1. We seek strategic partners in the IVF industry value chain, particularly genetic testing providers and manufacturers of next-generation sequencing reagents and instruments.

2. We seek strategic investors with strong interest in the biomedical sector, with a target fundraising amount of US$3 million.